Form 8-K - Current report:
SEC Accession No. 0001104659-25-064755
Filing Date
2025-07-01
Accepted
2025-07-01 16:31:32
Documents
13
Period of Report
2025-06-28
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2519577d1_8k.htm   iXBRL 8-K 31218
2 EXHIBIT 10.1 tm2519577d1_ex10-1.htm EX-10.1 84650
  Complete submission text file 0001104659-25-064755.txt   306436

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA otlk-20250628.xsd EX-101.SCH 3047
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE otlk-20250628_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE otlk-20250628_pre.xml EX-101.PRE 22380
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2519577d1_8k_htm.xml XML 3657
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 251096864
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)